Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Media News - September 16, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Investor Update - September 16, 2020 Category: Pharmaceuticals Source Type: news

HPV Test Is Preferred Method for Cervical Cancer Screening: ACS HPV Test Is Preferred Method for Cervical Cancer Screening: ACS
New guidelines recommend human papillomavirus (HPV) testing as the preferred screening method, but cotesting and cytology alone are still acceptable options.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 4, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

American Cancer Society now recommends cervical cancer screening start at 25, not 21
Individuals with a cervix are now recommended to start cervical cancers screening at 25 and continue through age 65, with the primary human papillomavirus (HPV) testing every five years as the preferred method of testing, according to a new guideline released Thursday by the American Cancer Society. (Source: CNN.com - Health)
Source: CNN.com - Health - July 31, 2020 Category: Consumer Health News Source Type: news

American Cancer Society Recommends HPV Test
The new guideline calls for an initial cervix screening at age 25, followed by the human papillomavirus (HPV) test every five years, continuing through age 65, the guideline says. (Source: WebMD Health)
Source: WebMD Health - July 31, 2020 Category: Consumer Health News Source Type: news

BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities
BD Onclarity™ HPV Assay is the only FDA-approved HPV assay to individually identify and report genotypes beyond 16, 18 and 45 FRANKLIN LAKES, N.J., July 22, 2020 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX... Diagnostics, Oncology, FDA BD , Onclarity, HPV Assay, human papillomavirus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2020 Category: Pharmaceuticals Source Type: news

AI dual-stain approach improved accuracy, efficiency of cervical cancer screening
(NIH/National Cancer Institute) In a new study, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Pap test), the current standard for follow-up of women who test positive with primary human papillomavirus (HPV) screening. The algorithm was developed and the study conducted by investigators at the National Cancer Institute (NCI), part of the National Institutes of Health, in collaboration with researchers from several other institutions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2020 Category: Cancer & Oncology Source Type: news

World First: Saliva Test Detects Occult HPV Oral Cancer World First: Saliva Test Detects Occult HPV Oral Cancer
A saliva test still under development has scored a world first: it led to a finding of oral cancer after detecting rising human papillomavirus DNA levels in subsequent oral rinses.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer
             Basel, 21 April 2020 - Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced US Food and Drug Administration (FDA) approval for the cobas ® HPV test for use on the fully automated, high-throughput cobas® 6800/8800 Systems. The cobas® HPV test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples. Persistent high-risk HPV infections can develop into pre cancerous lesions and, if left untreated, these lesions can progress to cervical cancer.“The approval ...
Source: Roche Media News - April 21, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer
Basel, 21 April 2020 - Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced US Food and Drug Administration (FDA) approval for the cobas ® HPV test for use on the fully automated, high-throughput cobas® 6800/8800 Systems. The cobas® HPV test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples. Persistent high-risk HPV infections can develop into p recancerous lesions and, if left untreated, these lesions can progress to cervical cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - April 21, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention
Basel, 11 March 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of CINtec®PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas ® 4800 HPV Test. This biomarker technology simplifies clinical decision making by providing easy to understand results so that clinicians and women are clear on next steps. The CINtecPLUS Cytology test identifies those women whose HPV infections are most likely to be associated with cervical pre-cancers. It...
Source: Roche Media News - March 11, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention
Basel, 11 March 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of CINtec®PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas ® 4800 HPV Test. This biomarker technology simplifies clinical decision making by providing easy to understand results so that clinicians and women are clear on next steps. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2020 Category: Pharmaceuticals Source Type: news

Cancer-causing HPV can hit you even if you had the vaccination
Jessica Donald, from Birmingham, thought she'd get the all-clear after a cervical cancer screening test at her GP - only to be told she'd tested positive for human papillomavirus. (Pictured, stock image.) (Source: the Mail online | Health)
Source: the Mail online | Health - February 9, 2020 Category: Consumer Health News Source Type: news

The incidence of oropharyngeal cancer and rate of human papillomavirus vaccination coverage in Florida, 2011 through 2015.
CONCLUSIONS:The authors found relatively higher and increasing incidence rate of OPC in Florida and lower rate of HPV vaccination among adolescents in Florida than in the nation overall.PRACTICAL IMPLICATIONS:The trends illustrated may stimulate policy changes to increase HPV vaccination for children and enhance the understanding of its benefits. (Source: Dental Technology Blog)
Source: Dental Technology Blog - January 23, 2020 Category: Dentistry Source Type: news

Cervical cancer could be on its way to extinction thanks to improved testing and vaccination
A new detection method rolled out last month looks for traces of the human papillomavirus (HPV), which cause nearly all cervical tumours. (Source: the Mail online | Health)
Source: the Mail online | Health - January 20, 2020 Category: Consumer Health News Source Type: news

Routine HPV Testing May Be Warranted for Sinonasal Cancers
FRIDAY, Jan. 3, 2020 -- Only one in four patients with sinonasal squamous cell carcinoma (SNSCC) is tested for human papillomavirus (HPV), according to a study published online Dec. 30 in Cancer. Jamie R. Oliver, from the New York University School... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2020 Category: Pharmaceuticals Source Type: news

Improved Saliva Test Aids Detection of HPV-16 Improved Saliva Test Aids Detection of HPV-16
Use of acoustofluidic separation technology (AFS) doubles detection of oropharyngeal cancer-associated human papillomavirus-16 (HPV-OPC) in saliva, according to an international group of investigatorsReuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 27, 2019 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

HPV Genotyping and Reflex Cytology Efficient for Cervical-Cancer Screening HPV Genotyping and Reflex Cytology Efficient for Cervical-Cancer Screening
Human papillomavirus (HPV) genotyping for HPV-16 and HPV-18, followed by reflex cytological testing in women with positive results, is more likely than cytological testing alone to detect cervical intraepithelial neoplasia (CIN) grade 2 or higher, according to results from the FRIDA study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 3, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Roche Packs New FDA-Approved Test in Its Arsenal
Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800/8800 system. Cobas Babesia detects parasites that live in red blood cells. Roche said this test is an important advancement because the Babesia parasite cannot be detected in traditional plasma or serum samples. The test can detect the four-common species of Babesia and employs the new whole blood collection tube, which simplifies Babesia sample preparation by consolidating steps within the tube itself to provide an efficient solutio...
Source: MDDI - September 20, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Regulatory and Compliance Source Type: news

Confused About Who Should Get the HPV Vaccine, and When? The CDC Has New Recommendations
For its first few years on the market, the human papillomavirus (HPV) vaccine was approved only for young girls. Over time, the U.S. Food and Drug Administration (FDA) has broadened its approval to include boys, as well as adults up to age 45—allowing more people to get the cancer-preventing vaccine, but also breeding confusion about who should get vaccinated and when. On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) released new recommendations, based on guidance from the Advisory Committee on Immunization Practices, that should clear up some of that confusion. The CDC reaffirmed that its prior...
Source: TIME: Health - August 15, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized onetime public health Source Type: news

Why Sexually Transmitted Infections Can ’t Shake Their Stigma
We live in an era of sex positivity — until we get positive test results. And that’s unfortunate, because S.T.I.s are on the rise. (Source: NYT Health)
Source: NYT Health - August 13, 2019 Category: Consumer Health News Authors: Jen Gunter Tags: your-feed-selfcare Sexually Transmitted Diseases Herpes Viruses Human Papillomavirus (HPV) your-feed-science your-feed-health Source Type: news

Roche Expands Global Access to Viral Assays to Aid Eradication Efforts
Roche has expanded the Global Access Program, originally established to increase availability of HIV diagnostics in underserved countries, to include diagnostic tests for tuberculosis, hepatitis, and human papillomavirus (HPV). Increased access to reliable diagnostics will allow early, possibly life-saving, detection and decrease the spread of these diseases. Roche launched the program in 2014 and began offering the added tests in July. The molecular diagnostics available include tests for determination of HIV-1 viral load, early diagnosis of HIV-1 and -2 in young infants, Mycobacterium tuberculosis (MTB) and rifampin/ison...
Source: MDDI - August 9, 2019 Category: Medical Devices Authors: Jenevieve Blair Polin Tags: IVD Source Type: news

Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
Roche announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. (Source: Roche Media News)
Source: Roche Media News - July 22, 2019 Category: Pharmaceuticals Source Type: news

Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
Roche announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. (Source: Roche Investor Update)
Source: Roche Investor Update - July 22, 2019 Category: Pharmaceuticals Source Type: news

Could Myriad ’s New Study Results Be Game Changers For Cancer Patients?
The 2019 American Society of Clinical Oncology’s meeting might be in the books, but the impact of some of the data released at the conference are certain to have implications for cancer patients for years to come. Myriad Genetics presented data from several studies at ASCO that will no doubt have a long-lasting impact on cancer detection and treatment. The Salt Lake City, UT-based company spoke with MD+DI during ASCO about results from both colorectal cancer and breast cancer studies. Some of the most talked-about results came from the Phase III POLO Study, which looked at how well the BRACAnalysis CDx id...
Source: MDDI - June 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

Some Cervical Cancer Screening Strategies More Cost-Effective
TUESDAY, May 14, 2019 -- A cervical cancer screening strategy that involves cytologic testing every three years from ages 21 to 29 years and then continuing cytologic testing or switching to low-cost high-risk human papillomavirus (hrHPV) testing... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 14, 2019 Category: Pharmaceuticals Source Type: news

The 4 Types of Doctors Visits You Should Make For a Long, Healthy Life
Prevention is often called the best medicine — but research has shown that millions of Americans are not getting the preventive care they should to live long, healthy lives. Obstacles like inadequate access to care and financial barriers can keep people away from the doctor, but anxiety and feeling like care is unnecessary are also common deterrents. “There are a lot of things that every person could do to stay healthy, and this could help people to feel better, improve their quality of life and help them to live longer,” says Dr. Alex Krist, a professor of family medicine at Virginia Commonwealth Univer...
Source: TIME: Health - May 10, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Longevity public health Source Type: news

DNA test is an effective cervical cancer screening tool for women in low-income countries
(Dartmouth-Hitchcock Medical Center) Dartmouth researchers have introduced an inexpensive DNA-based test for human papillomavirus (HPV), the cause of cervical cancer, in Honduras. The test aid can effectively be used to screen women who have never been screened for this deadly disease. Results of the initiative revealed not only high positivity rates of HPV but unexpected differences in the types of HPV compared to those found in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 3, 2019 Category: International Medicine & Public Health Source Type: news

DNA Test Is an Effective Cervical Cancer Screening Tool for Women in Low-Income Countries
Effective cervical cancer screening initiative by Dartmouth researchers in Honduras identifies different human papillomavirus types than those in the U.S. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - May 2, 2019 Category: Hospital Management Authors: NonPerson Geisel Web Service Acct Tags: News Research cancer cervical cancer Gregory Tsongalis HPV Norris Cotton Cancer Center Source Type: news

The Germiest Place in Your Bathroom Isn ’t Your Toilet
Have you hovered over a toilet seat in a public restroom, desperate not to touch it? Chances are good that you have. Americans are so grossed out by the thought of touching things in public bathrooms that 64% of people who use them flush the toilet with their feet, according to a 2013 survey, and 60% use paper towels to open bathroom doors. Several studies over the years have revealed that scary-sounding bacteria and viruses cover the surfaces of bathrooms. But there’s a lot you don’t know about the germs that lurk in the bathroom. Here are four surprising facts about the germs you encounter in restrooms at an...
Source: TIME: Health - April 25, 2019 Category: Consumer Health News Authors: Julissa Treviño Tags: Uncategorized public health Source Type: news

Cervical cancer subtype rising in some sub-populations
(American Cancer Society) A new study reports that a type of cervical cancer that is less amenable to Pap testing is increasing in several subpopulations of women, pointing to the growing importance of human papillomavirus (HPV) testing and vaccination (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2019 Category: International Medicine & Public Health Source Type: news

Sexually transmitted infections are on the rise. Here ’s what you need to know to protect yourself
UCLA Health Rates of sexually transmitted diseases have risen for the past four years to record highs in the United States, according to the Centers for Disease Control and Prevention ’slatest analysis. In California, the state health departmentfound that the number of people diagnosed with syphilis, gonorrhea or chlamydia in 2017 was 45 percent higher than five years prior.These sorts of statistics may spark a fear that there ’s little we can do to protect ourselves — but that’s not the full story.Dr. Leena Nathan, an obstetrician/gynecologist at UCLA Health-Westlake Village, consults with peo...
Source: UCLA Newsroom: Health Sciences - February 14, 2019 Category: Universities & Medical Training Source Type: news

New Study Finds Discrepancies in Cervical Cancer Screening Rates
A new Mayo Clinic study shows that the percentage of women who are screened for cervical cancer could be far lower than national data suggests. The researchers' findings were published in the Journal of Women’s Health and show that less than two thirds of women ages 30 to 65 were up-to-date with cervical cancer screenings in 2016. What’s telling is the percentage is even lower for women ages 21 to 29, with just over half current on screenings. Mayo Clinic Researchers said those figures are well below the 81% screening compliance rate that was self-reported in the 2015 National Health Int...
Source: MDDI - January 7, 2019 Category: Medical Devices Authors: MDDI Staff Tags: IVD Testing Source Type: news

New epigenetic cervical cancer test has 100 per cent detection rate
(Queen Mary University of London) A new test for cervical cancer was found to detect all of the cancers in a trial of 15,744 women, outperforming both the current Pap smear and human papillomavirus (HPV) test at a reduced cost, according to a study by Queen Mary University of London. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2018 Category: Cancer & Oncology Source Type: news

Mail-Based HPV Testing May Increase Access
TUESDAY, Dec. 11, 2018 -- A mail-based human papillomavirus (HPV) self-testing program appears to be a promising approach to screening women in Appalachia, according to a pilot study published online Nov. 19 in Sexually Transmitted Diseases. Paul L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2018 Category: Pharmaceuticals Source Type: news

Increased cervical cancer risk in women with positive HPV, but no cellular abnormalities
(Wiley) Researchers have uncovered an increased risk of cervical cancer in women whose cervical cells test positive for certain high-risk human papillomavirus (HPV) types but do not show any signs of cellular abnormalities. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help refine guidelines for cervical cancer screening. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2018 Category: Cancer & Oncology Source Type: news

Mailed HPV Tests Help Identify Women At Risk for Cervical Cancer Mailed HPV Tests Help Identify Women At Risk for Cervical Cancer
Kits to self-test for human papillomavirus (HPV) mailed to underserved women helped to identify virtually all of those with high-risk HPV oncogenic types, in a proof-of-principle study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Age to Stop Cervical Cancer Screening Depends on Test Used
FRIDAY, Nov. 2, 2018 -- Continuing regular cytology screening up to age 75 years or performing an exit human papillomavirus (HPV) test to confirm the absence of oncogenic HPV strains past the age of 55 years offers preventive benefit for older women... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 2, 2018 Category: Pharmaceuticals Source Type: news

How Necessary Is HPV Cervical Cancer Screening for Women After Age 55?
FRIDAY, Nov. 2, 2018 -- Testing for human papillomavirus (HPV) has become the standard of care in screening for cervical cancer. But now, Canadian researchers say it may become unnecessary in women aged 55 or older who have one negative result with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 2, 2018 Category: General Medicine Source Type: news

Liquid Biopsy Confirms Remission in HPV Oropharyngeal Cancer Liquid Biopsy Confirms Remission in HPV Oropharyngeal Cancer
A plasma circulating tumor human papillomavirus (HPV) DNA test had a negative predictive value of 100% and predicts patients at risk for cancer recurrence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Quiz: Cancers Associated with Human Papillomavirus
Cervical cancer is the most common HPV-associated cancer. What are some of the others? Take our quiz to test your knowledge. (Source: CancerNetwork)
Source: CancerNetwork - October 10, 2018 Category: Cancer & Oncology Source Type: news

Adults Up to Age 45 Can Now Get the HPV Vaccine
Adults up to age 45 can now be vaccinated against human papillomavirus (HPV), reducing their chances of getting cervical, oral and other cancers. The Food and Drug Administration (FDA) announced Friday that Gardasil 9, a vaccine that works against nine different types of HPV, is now approved for both men and women between the ages of 27 and 45. Previously, it was approved only for those between the ages of nine and 26, and recommended for all children at age 11 or 12. “Today’s approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,” Dr. Peter M...
Source: TIME: Health - October 6, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime public health Source Type: news

HPV Testing Can Replace Pap Smears for Many Women, New Guidelines Say
Pap smears, long the gold standard for cervical cancer screening, may be used less frequently under new guidelines from the U.S. Preventive Services Task Force. The recommendations, which were published Tuesday in JAMA, say that women between ages 30 and 65 can rely on human papillomavirus (HPV) testing instead of, or in addition to, Pap smears. Women in this age group should get HPV testing every five years, a Pap smear every three years or a combination of the two tests every five years, the guidelines say. HPV causes the vast majority of cervical cancer cases, according to the National Cancer Institute, which makes HPV ...
Source: TIME: Health - August 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Innovation Health onetime Source Type: news

HPV Test May Replace Pap for Some Women, New Guidelines Say
TUESDAY, Aug. 21, 2018 -- The Pap smear has long been the gold standard for cervical cancer screening, but an expert panel now says the HPV (human papillomavirus) test is also an option for women over 30. These women now have three choices under... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 21, 2018 Category: General Medicine Source Type: news

Roche is on the “SurePath” for Cervical Cancer Screening with Approval
Roche has won a monumental approval from FDA that stands to enhance its cervical cancer detection offerings. The Basel, Switzerland-based company has received a nod for its cobas Human Papillomavirus (HPV) Test as a first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid. "Before today, laboratories did not have an FDA-approved HPV test available that could cover all of the HPV screening options supported in professional guidelines and be used with both of the primary Pap test collection media," Ann Costello, Head of Roche Tissue Diagno...
Source: MDDI - August 3, 2018 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

Massive failure in cervical cancer screening prompts Ireland to overhaul testing
Irish health authorities will start screening women for cervical cancer with a test for human papillomavirus (HPV) — something a Canadian study recently recommended. (Source: CBC | Health)
Source: CBC | Health - July 9, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

What is the Interval For Non-simultaneous Administration of Live Virus Vaccines?
Discussion Vaccines are a mainstay of infectious disease prevention and health promotion. Infants, children and adults benefit from vaccines the most when they are given on the recommended schedules. However there are times when this is not possible as children come to the physician a little early, or a little late, or had unavailable records and so received addition vaccine, etc. There are many questions that arise because of these timing issues such as the one above. Standard vaccine schedules can be reviewed here. Commonly administered vaccines includes: Live-attenuated vaccines Cholera Measles, mumps, rubella (MMR ...
Source: PediatricEducation.org - July 9, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

HPV test is better than Pap smear at detecting precancerous cervical changes, study says
A test for HPV detects precancerous changes of the cervix earlier and more accurately than the Pap smear, according to a large clinical trial published Tuesday.The randomized, controlled study — the kind of trial considered the "gold standard" of research — showed that the human papillomavirus... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - July 4, 2018 Category: Science Authors: Laurie McGinley Source Type: news

HPV Cervical CA Screening Cuts Odds of Later CIN3 & #43; Diagnosis
TUESDAY, July 3, 2018 -- The use of primary human papillomavirus (HPV) testing versus cytology results in reduced likelihood of cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) at 48 months, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 3, 2018 Category: Pharmaceuticals Source Type: news

HPV test tops Pap smear in cancer screening study
A new study finds that testing for the human papillomavirus or HPV was linked with significantly fewer cases of precancer in a 48-month period -- meaning the precancer was detected earlier -- compared with using pap smear testing. (Source: CNN.com - Health)
Source: CNN.com - Health - July 3, 2018 Category: Consumer Health News Source Type: news